Vandetanib

Overview
Vandetanib (rINN, trade name Zactima), also known as ZD6474, is a medication currently undergoing clinical trials as a potential targeted treatment for non–small-cell lung cancer. It is an antagonist of the vascular endothelial growth factor receptor (VEGFR) and the epidermal growth factor receptor (EGFR).

Vandetanib is being developed by AstraZeneca.